This study, called SISTER, is testing a new treatment called TS23 for people who have had an acute ischemic stroke. TS23 is a monoclonal antibody, a type of protein that can target specific substances in the body. The study aims to see if TS23 is safe and effective in improving stroke recovery. You might be able to join if you are 18 or older, have had a suspected acute ischemic stroke affecting the front part of your brain, and have a certain level of stroke severity (NIH Stroke Scale score of 4 or more). Doctors will also look at your brain scans to make sure you have salvageable brain tissue. The study will enroll up to 300 participants and will measure safety by looking at any bleeding in the brain, and effectiveness by checking your stroke severity after treatment.

Study design

This is a Phase II, randomized, placebo-controlled, blinded study that will enroll up to 300 participants. It uses an adaptive design to test different doses of TS23 against a placebo.

What's involved

After providing informed consent, you would be randomized to receive one of four doses of TS23 or a placebo. Your stroke severity and any bleeding in the brain will be measured about 30 hours after receiving the study drug.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 90 (+/-7) days after receiving the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.